Skip to main content
Top
Published in: BMC Infectious Diseases 3/2014

Open Access 01-05-2014 | Poster presentation

Transcriptional and translational analysis of subsequent infection with Staphylococcus aureus and Proteus mirabilis in Caenorhabditis elegans

Authors: Udayakumar Prithika, Gnanasekaran JebaMercy, Krishnaswamy Balamurugan

Published in: BMC Infectious Diseases | Special Issue 3/2014

Login to get access

Excerpt

Caenorhabditis elegans can be effectively used to study the dynamics of polymicrobial infections. Proteus mirabilis as an opportunistic pathogen does not cause death in C. elegans. Hence, in the present study, the C. elegans was pre infected with the pathogen Staphylococcus aureus to make the C. elegans immuno compromised to study the effect of P. mirabilis in the host. …
Metadata
Title
Transcriptional and translational analysis of subsequent infection with Staphylococcus aureus and Proteus mirabilis in Caenorhabditis elegans
Authors
Udayakumar Prithika
Gnanasekaran JebaMercy
Krishnaswamy Balamurugan
Publication date
01-05-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue Special Issue 3/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-14-S3-P7

Other articles of this Special Issue 3/2014

BMC Infectious Diseases 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine